Gufic Biosciences Limited
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹19.58 billion
- Book Value:
- Revenue TTM:
- ₹6.80 billion
- Operating Margin TTM:
- Gross Profit TTM:
- ₹3.58 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Gufic Biosciences Limited had its IPO on under the ticker symbol GUFICBIO.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Gufic Biosciences Limited has a staff strength of 1,382 employees.
Shares of Gufic Biosciences Limited opened at ₹209.1 at the start of the last trading session i.e. 2023-05-30.
The stocks traded within a range of ₹206.2 - ₹212.1, and closed at ₹210.2.
This is a +1.28% increase from the previous day's closing price.
A total volume of 77,428 shares were traded at the close of the day’s session.
In the last one week, shares of Gufic Biosciences Limited have increased by +3.29%.
Gufic Biosciences Limited's Key Ratios
Gufic Biosciences Limited has a market cap of ₹19.58 billion, indicating a price to book ratio of 6.9111 and a price to sales ratio of 3.1702.
In the last 12-months Gufic Biosciences Limited’s revenue was ₹6.80 billion with a gross profit of ₹3.58 billion and an EBITDA of ₹1.28 billion. The EBITDA ratio measures Gufic Biosciences Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Gufic Biosciences Limited’s operating margin was 16.58% while its return on assets stood at 0% with a return of equity of 0%.
In Q4, Gufic Biosciences Limited’s quarterly earnings growth was a negative -3.2% while revenue growth was a positive 3.1%.
Gufic Biosciences Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹8.44 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Gufic Biosciences Limited’s profitability.
Gufic Biosciences Limited stock is trading at a EV to sales ratio of 3.3769 and a EV to EBITDA ratio of 17.3266. Its price to sales ratio in the trailing 12-months stood at 3.1702.
Gufic Biosciences Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0.05% and a payout ratio of 3.15%.
Balance sheet and cash flow metrics
- Total Assets
- ₹6.95 billion
- Total Liabilities
- ₹2.55 billion
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Gufic Biosciences Limited ended 2023 with ₹6.95 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹6.95 billion while shareholder equity stood at ₹3.09 billion.
Gufic Biosciences Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹2.55 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹294.87 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹1.12 billion.
Gufic Biosciences Limited’s total current assets stands at ₹4.35 billion while long-term investments were ₹0 and short-term investments were ₹167.79 million. Its net receivables were ₹1.88 billion compared to accounts payable of ₹1.45 billion and inventory worth ₹1.68 billion.
In 2023, Gufic Biosciences Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Gufic Biosciences Limited paid ₹0.03 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Gufic Biosciences Limited stock is currently trading at ₹210.2 per share. It touched a 52-week high of ₹242.5857 and a 52-week low of ₹242.5857. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹200.3 and 200-day moving average was ₹212.54 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7811.5% of the company’s stock are held by insiders while 108.3% are held by institutions.
Frequently Asked Questions About Gufic Biosciences Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.